Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...

The PREDICT-RT study stratifies enrolled patients with high-risk cancer by Decipher Risk Score. Decipher testing was conducted by Veracyte, Inc. (VCYT), a global diagnostics company that provides high ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests “The breadth of data at ASCO GU ...

PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...

VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.